Trump Slaps 100% Tariff on Imported Branded Drugs

U.S. President Donald Trump announced a 100% tariff on branded and patented pharmaceutical imports, effective October 1, 2025, unless foreign companies establish manufacturing facilities in the United States.

Impact on India

• Generics excluded on paper: India, the world’s largest supplier of generics to the U.S., exports about $20 billion annually, supplying nearly 40% of U.S. generics.
• Major exporters: Sun Pharma, Dr Reddy’s Laboratories, Cipla, Lupin, and Aurobindo Pharma.
• Relief but uncertainty: While generics are not directly hit, the policy raises fears of future restrictions.

Market Distortions

• Short-term effect: Branded drugs could become costlier, potentially boosting demand for generics.
• Long-term risk: Washington may tighten controls on imports and accelerate efforts to build domestic production of low-cost generics.

The move is seen as part of Trump’s “America First” industrial push, but it risks unsettling the $20 billion India–U.S. pharmaceutical trade and reshaping the U.S. drug pricing landscape.